Clinical Trials Browser

Active not recruiting × INDUSTRY × trastuzumab deruxtecan × Clear all

NCT04494425 2026-03-04

DB-06

Phase 3 Active not recruiting

866 enrolled 25 charts 1 FDA

Breast Neoplasms

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT04739761 2026-02-11

DESTINY-B12

Phase 3 Active not recruiting

506 enrolled 27 charts

Brain Neoplasms, Breast Neoplasms

NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Solid Cancer

NCT03742102 2026-02-02

BEGONIA

Phase 1/2 Active not recruiting

243 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04704934 2026-01-12

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Phase 3 Active not recruiting

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT05048797 2025-12-23

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04556773 2025-12-17

DB-08

Phase 1 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04538742 2025-12-08

DB-07

Phase 1/2 Active not recruiting

Brain Neoplasms, Breast Neoplasms

NCT04042701 2025-11-18

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT03529110 2025-10-21

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Phase 3 Active not recruiting

524 enrolled 11 charts 1 FDA

Breast Neoplasms

NCT04639219 2025-10-16

DPT01

Phase 2 Active not recruiting

102 enrolled 18 charts

Neoplasm Metastasis

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3 Active not recruiting

557 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT05246514 2025-08-28

DL-05

Phase 2 Active not recruiting

72 enrolled 16 charts

HER2-mutant Non-Small Cell Lung Cancer

NCT05765851 2025-05-11

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

Breast Neoplasms

NCT04622319 2025-05-09

DESTINY-Breast05

Phase 3 Active not recruiting

HER2-Positive Primary Breast Cancer